API Technologies Corp. (NASDAQ: ATNY) announced the addition of high reliability MIL grade SMPS ceramic capacitors to its Spectrum Control product line. These high-speed switch mode power supply (SMPS) capacitors feature extremely low equivalent series resistance (ESR) and equivalent series inductance (ESL), as well as predictable performance characteristics with changes in temperature, voltage and frequency. They are ideal for high reliability and high frequency applications. A commercial industrial grade alternative in a non-military package configuration is also available. The company has also received a $8.1 million order for its Electronics Manufacturing Services (EMS) business unit to provide electronics solutions for tactical surveillance systems. The order was placed by a Fortune 100 company repeat customer and is scheduled to be delivered over the next nine months.
http://www.apitech.com
Attolight announces that it has raised CHF 1.5m from both institutional and private investors: these include Aargauische Kantonalbank, Zürcher Kantonalbank, StartAngels Network and Verve Capital Partners. The active participation of the existing investors in this 2nd financing round reinforces their confidence in Attolight.
Leti is announcing a new collaboration with the Swiss company Attolight to develop cathodoluminescence technology for more applications. Attolight’s innovative technology combines electron and light microscopy to reveal ultra-trace impurities and crystallographic defects that are not visible using other imaging techniques.
http://www.leti.fr http://www.attolight.com/
Arrowhead Research Corporation (NASDAQ: ARWR) received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application US 13/032,029 entitled, "Compositions for Targeted Delivery of siRNA." The patent broadly covers compositions, methods, and uses for a new formulation of Arrowhead’s Dynamic Polyconjugate (DPC) siRNA delivery platform, where attachment of siRNA and delivery vehicle is not required to produce high-level, efficient knockdown of target genes. The new IP expands the DPC platform and is used in Arrowhead’s ARC-520 candidate in development for chronic hepatitis B virus (HBV) infection.
http://www.arrowheadresearch.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93